Flexion Therapeutics, Inc. (NASDAQ:FLXN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “

Several other analysts have also recently issued reports on the company. Cantor Fitzgerald set a $40.00 target price on Flexion Therapeutics and gave the stock a “buy” rating in a research report on Monday, May 22nd. Needham & Company LLC reiterated a “buy” rating and set a $34.00 target price on shares of Flexion Therapeutics in a research report on Monday, May 15th. ValuEngine upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Janney Montgomery Scott reiterated a “buy” rating and set a $35.00 target price (up previously from $30.00) on shares of Flexion Therapeutics in a research report on Wednesday, July 12th. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $44.00 target price on shares of Flexion Therapeutics in a research report on Friday, July 7th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $32.09.

Flexion Therapeutics (NASDAQ:FLXN) opened at 24.33 on Monday. The firm’s market capitalization is $776.25 million. The company has a 50 day moving average of $23.03 and a 200 day moving average of $21.52. Flexion Therapeutics has a 1-year low of $15.44 and a 1-year high of $29.41.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by $0.11. On average, equities research analysts anticipate that Flexion Therapeutics will post ($3.70) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Upgrades Flexion Therapeutics, Inc. (FLXN) to “Hold”” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/30/zacks-investment-research-upgrades-flexion-therapeutics-inc-flxn-to-hold.html.

In other news, insider Michael D. Clayman purchased 5,000 shares of the business’s stock in a transaction on Monday, June 5th. The stock was acquired at an average price of $17.23 per share, for a total transaction of $86,150.00. Following the acquisition, the insider now directly owns 20,146 shares of the company’s stock, valued at approximately $347,115.58. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark Stejbach purchased 1,580 shares of the business’s stock in a transaction on Friday, June 16th. The shares were purchased at an average price of $17.02 per share, with a total value of $26,891.60. The disclosure for this purchase can be found here. Company insiders own 15.98% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Fiduciary Trust Co. purchased a new position in Flexion Therapeutics during the second quarter valued at $101,000. IFP Advisors Inc boosted its position in Flexion Therapeutics by 24.5% in the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 1,000 shares in the last quarter. Advisor Group Inc. boosted its position in Flexion Therapeutics by 205.9% in the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 3,500 shares in the last quarter. Monarch Partners Asset Management LLC purchased a new position in Flexion Therapeutics during the first quarter valued at $279,000. Finally, Asset Management One Co. Ltd. purchased a new position in Flexion Therapeutics during the first quarter valued at $319,000. Institutional investors and hedge funds own 82.75% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.